Compare AbCellera Biologics Inc (ABCL) vs Bank of Montreal (BMO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs Bank of Montreal — how do they compare? AbCellera Biologics Inc trades at $7.18 (market cap $2.35B), while Bank of Montreal trades at $174.7 (market cap $124.94B). The key difference: Bank of Montreal is far larger — about 53.2× AbCellera Biologics Inc's market cap, and Bank of Montreal pays a 2.78% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | BMO | |
|---|---|---|
Market Cap | $2.35B | $124.94B |
Sector | Health | Financials |
52-Week High | $8.12 | $178.25 |
52-Week Low | $2.78 | $110.44 |
Enterprise Value | $1.99B | — |
Dividend Yield | — | 2.78% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
BMO trades at $178.25, up 2.37% today, with a bullish technical signal and strong analyst support. Recent earnings show a mixed record with a Q1 2026 miss but beats in prior quarters, while revenue and net income have grown steadily. The company maintains a solid dividend history and was recently recognized as Best Commercial Bank in Canada and the U.S. by World Finance Magazine (June 23, 2026).
The outlook is positive given earnings growth and strategic acquisitions, but risks include valuation above historical averages and sensitivity to interest rates. Analyst consensus is evenly split between Buy and Hold, indicating cautious optimism for continued performance amid economic uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Bank of Montreal
Bank of Montreal is a diversified financial-services provider based in North America, operating four business segments: Canadian personal and commercial banking, U.S. P&C banking, wealth management, and capital markets. The bank's operations are primarily in Canada, with a material portion also in the U.S.
Read more on BMO →
